History has shown that some of the most innovative and successful companies have been built during challenging times as teams, both small and large, are forced to stay lean, swiftly build value and execute only the most essential priorities with limited budgets. This market is no different, and to that end we continue to be active and inspired by opportunities at the earliest stages.
We’re witnessing an explosion in engineered, programmable medicines and tech-enabled healthcare innovation across the expanding techbio landscape. Many of our companies are both improving lives by increasing access to care as well as helping to better diagnose, prevent, and treat disease, ranging from cardiovascular to cancer to infectious disease and many more. The intersection of computer science and medicine is not just relevant to the next 5 years, but to the next 50+ years. As long as there are humans, as long as there is disease, as long as there are problems to solve, we will be solving them.
Nearly $1B of
Exits & New Investments
Pioneering Gene Writing to write therapeutic messages into the genome to treat diseases at their source.
Re-imagining addiction treatment for the digital age.
Improving access to care through a one-stop-shop telemedicine and prescription delivery solution across key European markets.
Designing RNA molecules using deep learning experiments to make mRNA medicines more effective
Pre-recorded therapy sessions to help users navigate their mental health needs anonymously, anytime and anywhere.
Innovating biology-driven technology to expand on brain interface development.